- Home
- APRE vs ARTW Comparison
APRE vs ARTW Comparison
Compare APRE & ARTW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | APRE | ARTW |
|---|---|---|
| Founded | 2006 | 1956 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Industrial Machinery/Components |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.5M | 13.4M |
| IPO Year | 2019 | 1996 |
Fundamental Metrics
Financial Performance| Metric | APRE | ARTW |
|---|---|---|
| Price | $0.63 | $2.19 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $4.10 | N/A |
| AVG Volume (30 Days) | ★ 57.0K | 12.2K |
| Earning Date | 05-13-2026 | 04-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 21.22 | ★ 233.33 |
| EPS | N/A | ★ 0.04 |
| Revenue | N/A | ★ $22,975,408.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $53.63 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.55 | $2.05 |
| 52 Week High | $1.93 | $4.69 |
Technical Indicators
Market Signals| Indicator | APRE | ARTW |
|---|---|---|
| Relative Strength Index (RSI) | 40.85 | 31.53 |
| Support Level | $0.57 | $2.07 |
| Resistance Level | $0.83 | $2.52 |
| Average True Range (ATR) | 0.06 | 0.09 |
| MACD | -0.01 | -0.03 |
| Stochastic Oscillator | 34.44 | 15.64 |
Price Performance
Historical ComparisonAbout APRE Aprea Therapeutics Inc.
Aprea Therapeutics Inc is a clinical-stage precision medicine oncology company focused on the discovery and development of targeted therapies for patients with biomarker-defined cancers. It develops small molecule inhibitors designed to exploit genetic mutations in cancer to widen the therapeutic window and is intended to make treatments more effective at destroying cancer cells while sparing healthy tissue. The company's pipeline of clinical and preclinical programs includes APR-1051, a WEE1 inhibitor; ATRN-119 (Mosipasertib), an oral small molecule inhibitor of ataxia telangiectasia and Rad3-related, or ATR; and an early-stage program, APR-1602. These candidates are being developed for broad applications in cancer treatment.
About ARTW Art's-Way Manufacturing Co. Inc.
Art's-Way Manufacturing Co Inc is a manufacturer of agricultural equipment. It has two reportable segments: Agricultural Products and Modular Buildings. The Agricultural Products segment fabricates and sells farming products as well as related equipment and replacement parts for these products in the United States and world wide. Its Modular Buildings segment manufactures and installs modular buildings for animal containment and various laboratory uses. It derives revenues from the Agricultural Products segment.